Founded in 2011 and currently a Series A company, Meditope focuses on developing next-generation oncology therapeutics through its innovative platform. The company has raised a total of $5.22M across 2 funding rounds, with its first Series A round completed in February 2013. With a lean team focused on bioconjugation technology and antibody-drug conjugate development, Meditope positions itself in the competitive antibody therapeutics space.
Cyborg Score Rationale
Meditope operates with a proprietary, differentiated SnAP platform and has attracted experienced board members with deep antibody expertise. However, the company remains very early-stage (15 years post-founding, still Series A) with minimal revenue (~$4M), a small team (5 employees), and limited recent visible progress. The preclinical-stage pipeline and limited funding ($5.22M total) suggest long development timelines ahead.
Top Insights
The SnAP platform was discovered at City of Hope (a National Cancer Institute designated Comprehensive Cancer Center) and enables site-specific attachment without chemical conjugation, offering a potential competitive advantage in antibody-drug conjugate engineering.
As of May 2025, Meditope had approximately 5 employees, maintaining an extremely lean research-focused operation.
In May 2018, Sanofi initiated a research collaboration with Meditope to explore bioconjugation technology, signaling validation from a major pharma partner.
The company reported annual revenue of $4 million in 2026, indicating early-stage commercialization or partnership revenues.
Named Competitors
Jazz Pharmaceuticals — Oncology and specialty pharmaceutical company
Sana Biotechnology — Cell therapy platform for oncology and immune diseases